171 related articles for article (PubMed ID: 11903325)
21. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Vanecková I; Kramer HJ; Bäcker A; Schejbalová S; Vernerová Z; Eis V; Opocenský M; Dvorák P; Cervenka L
Vascul Pharmacol; 2006 Sep; 45(3):163-70. PubMed ID: 16807127
[TBL] [Abstract][Full Text] [Related]
22. Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression.
Li JS; Deng LY; Grove K; Deschepper CF; Schiffrin EL
Hypertension; 1996 Aug; 28(2):188-95. PubMed ID: 8707380
[TBL] [Abstract][Full Text] [Related]
23. Interaction between endothelin and angiotensin II.
Phillips PA
Clin Exp Pharmacol Physiol; 1999 Jul; 26(7):517-8. PubMed ID: 10405777
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin II and endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page hypertension.
Massart PE; Hodeige DG; Van Mechelen H; Charlier AA; Ketelslegers JM; Heyndrickx GR; Donckier JE
J Hypertens; 1998 Jun; 16(6):835-41. PubMed ID: 9663924
[TBL] [Abstract][Full Text] [Related]
25. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Muller DN; Mervaala EM; Schmidt F; Park JK; Dechend R; Genersch E; Breu V; Löffler BM; Ganten D; Schneider W; Haller H; Luft FC
Hypertension; 2000 Aug; 36(2):282-90. PubMed ID: 10948091
[TBL] [Abstract][Full Text] [Related]
26. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
27. Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.
Stevens EJ; Tomlinson DR
Br J Pharmacol; 1995 May; 115(2):373-9. PubMed ID: 7670740
[TBL] [Abstract][Full Text] [Related]
28. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist.
Li JS; Schiffrin EL
Hypertension; 1995 Apr; 25(4 Pt 1):495-500. PubMed ID: 7721389
[TBL] [Abstract][Full Text] [Related]
29. Chronic blockade of nitric oxide-synthase and endothelin receptors during pregnancy in the rat: effect on pregnancy outcome.
Wight E; Küng CF; Moreau P; Takase H; Lüscher TF
J Soc Gynecol Investig; 1998; 5(3):132-9. PubMed ID: 9614642
[TBL] [Abstract][Full Text] [Related]
30. Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates.
Bartholomeusz B; Hardy KJ; Nelson AS; Phillips PA
J Hum Hypertens; 1998 Dec; 12(12):839-44. PubMed ID: 9883706
[TBL] [Abstract][Full Text] [Related]
31. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II.
Ortiz MC; Sanabria E; Manriquez MC; Romero JC; Juncos LA
Hypertension; 2001 Feb; 37(2 Pt 2):505-10. PubMed ID: 11230326
[TBL] [Abstract][Full Text] [Related]
32. End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Vernerová Z; Kujal P; Kramer HJ; Bäcker A; Cervenka L; Vaneckova I
Physiol Res; 2009; 58 Suppl 2():S69-S78. PubMed ID: 20131938
[TBL] [Abstract][Full Text] [Related]
33. Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats.
Opocenský M; Dvorák P; Malý J; Kramer HJ; Bäcker A; Kopkan L; Vernerová Z; Tesar V; Zima T; Bader M; Ganten D; Janda J; Vanecková I
Physiol Res; 2004; 53(6):581-93. PubMed ID: 15588125
[TBL] [Abstract][Full Text] [Related]
34. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats.
Li JS; Schiffrin EL
J Hypertens; 1995 Jun; 13(6):647-52. PubMed ID: 7594422
[TBL] [Abstract][Full Text] [Related]
35. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.
Inscho EW; Imig JD; Deichmann PC; Cook AK
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S178-83. PubMed ID: 9892160
[TBL] [Abstract][Full Text] [Related]
36. Relative roles of endothelin-1 and angiotensin II in experimental post-ischaemic acute renal failure.
Jerkić M; Miloradović Z; Jovović D; Mihailović-Stanojević N; Elena JV; Nastić-Mirić D; Grujić-Adanja G; Rodríguez-Barbero A; Marković-Lipkovski J; Vojvodić SB; Manero MV; Prieto MP; López-Novoa JM
Nephrol Dial Transplant; 2004 Jan; 19(1):83-94. PubMed ID: 14671043
[TBL] [Abstract][Full Text] [Related]
37. Endothelin mediates some of the renal actions of acutely administered angiotensin II.
Riggleman A; Harvey J; Baylis C
Hypertension; 2001 Jul; 38(1):105-9. PubMed ID: 11463769
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
Iwanaga Y; Kihara Y; Inagaki K; Onozawa Y; Yoneda T; Kataoka K; Sasayama S
Circulation; 2001 Jul; 104(5):606-12. PubMed ID: 11479261
[TBL] [Abstract][Full Text] [Related]
39. [The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Gu Y; Chen J; Yang H; Zhu W; Lin F; Zhu C; Lin S
Zhonghua Yi Xue Za Zhi; 2002 Jan; 82(1):10-3. PubMed ID: 11953118
[TBL] [Abstract][Full Text] [Related]
40. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism.
Karam H; Heudes D; Bruneval P; Gonzales MF; Löffler BM; Clozel M; Clozel JP
Hypertension; 1996 Sep; 28(3):379-85. PubMed ID: 8794820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
